Gilead Sciences Inc. has released positive late-stage data for hepatitis C drug of the company. The company received FDA approval for Sovaldi on December 6, 2013 and is planning to file with FDA for approval of another drug ledipasvir. The combination of both drugs has been found very effective in cure of high percentage of hepatitis C cases.
As per new research by Dana-Farber Cancer Institute team, adding Velcade to standard preventive therapy for graft-versus host disease (GVHD) offering much better result for patients accepting stem-cell transplant from unrelated donors. Lead author to the study, John Koreth, MBBS, DPhil added that the regimen improved the acceptance of stem cells.
Graphene has been termed as thinnest and strongest material known so far. In a research paper published in journal AIP Advances, team of researcher from Boulder, Colorado has managed to create thin films of Graphene in a two-step process. Graphene could find application in creating cheaper solar cells, space suits, electric circuits and sensors.